Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant MenB and MenACWY vaccination in healthy adolescents aged 16-18 years
2016-003722-16Phase 3
- Sponsor
- GSK
- Start
- May 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Multicomponent meningococcal B vaccine and meningococcal conjugate vaccine in meningococcal disease and meningitis (2 arms), sponsored by GSK. Primary endpoint: Percentage of subjects with solicited local adverse events.
02
Drugs
Multicomponent meningococcal B vaccinemeningococcal conjugate vaccine
03
Conditions
meningococcal diseasemeningitis
Beyond the preview
Go deeper on 2016-003722-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003722-16.